In last trading session, Skye Bioscience Inc (NASDAQ:SKYE) saw 2.2 million shares changing hands with its beta currently measuring 1.78. Company’s recent per share price level of $4.25 trading at $0.56 or 15.18% at ring of the bell on the day assigns it a market valuation of $131.68M. That closing price of SKYE’s stock is at a discount of -98.59% from its 52-week high price of $8.44 and is indicating a premium of 73.18% from its 52-week low price of $1.14. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.61 million shares which gives us an average trading volume of 1.05 million if we extend that period to 3-months.
For Skye Bioscience Inc (SKYE), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Skye Bioscience Inc (NASDAQ:SKYE) trade information
Upright in the green during last session for gaining 15.18%, in the last five days SKYE remained trading in the green while hitting it’s week-highest on Thursday, 06/26/25 when the stock touched $4.25 price level, adding 8.99% to its value on the day. Skye Bioscience Inc’s shares saw a change of -49.40% in year-to-date performance and have moved 98.60% in past 5-day. Skye Bioscience Inc (NASDAQ:SKYE) showed a performance of 93.18% in past 30-days. Number of shares sold short was 2.82 million shares which calculate 12.09 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 20 to the stock, which implies a rise of 78.75% to its current value. Analysts have been projecting 15 as a low price target for the stock while placing it at a high target of 21. It follows that stock’s current price would drop -252.94% in reaching the projected high whereas dropping to the targeted low would mean a loss of -252.94% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 42.99% during past 5 years.
Skye Bioscience Inc (NASDAQ:SKYE)’s Major holders
Insiders are in possession of 1.44% of company’s total shares while institution are holding 80.79 percent of that, with stock having share float percentage of 81.98%. Investors also watch the number of corporate investors in a company very closely, which is 80.79% institutions for Skye Bioscience Inc that are currently holding shares of the company. 5AM VENTURE MANAGEMENT, LLC is the top institutional holder at SKYE for having 10.18 million shares of worth $81.54 million. And as of 2024-06-30, it was holding 26.3245 of the company’s outstanding shares.
The second largest institutional holder is VERSANT VENTURE MANAGEMENT, LLC, which was holding about 2.01 million shares on 2024-06-30. The number of shares represents firm’s hold over 5.192 of outstanding shares, having a total worth of $16.08 million.
